71136
document
Icosapent Ethyl ( Eicosapentaenoic Acid Ethyl Ester ) : Effects Upon High-Sensitivity C-Reactive Protein and Lipid Parameters in Patients With Metabolic Syndrome . BACKGROUND The aim of this analysis was to examine the effects of icosapent ethyl ( eicosapentaenoic acid ethyl ester , IPE ) on high-sensitivity C-reactive protein ( hsCRP ) and lipid parameters in patients with metabolic syndrome , with and without stable statin therapy . METHODS This post hoc exploratory analysis evaluated patients with metabolic syndrome treated with IPE 4 grams/day , IPE 2 grams/day , or placebo in phase 3 , randomized , placebo-controlled studies entitled : MARINE [ triglyceride ( TG ) levels ≥500 and ≤2000 mg/dL ] and ANCHOR [ TG levels ≥200 and < 500 mg/dL , despite low-density lipoprotein cholesterol ( LDL-C ) control with stable statin therapy ] . RESULTS Compared with placebo in patients with metabolic syndrome in MARINE ( n=204 ) and ANCHOR ( n=645 ) , at the approved dose of 4 grams/day , IPE significantly lowered hsCRP levels 40.0 % ( P=0.0007 ) in MARINE and 23.0 % ( P=0.0003 ) in ANCHOR . Compared with placebo in MARINE , which included patients with and without statin therapy , IPE 4 grams/day significantly reduced hsCRP levels 78.0 % in statin-treated patients ( P=0.0035 , n=16 ) . Compared with placebo in MARINE , IPE 4 grams/day significantly reduced TG levels ( 35.0 % ; P < 0.0001 ) , non-high-density lipoprotein cholesterol ( non-HDL-C ; 19.9 % ; P < 0.0001 ) , and apolipoprotein B levels ( ApoB ) ( 9.1 % ; P=0.0015 ) without raising LDL-C levels . Compared with placebo in ANCHOR , IPE 4 grams/day significantly reduced TG ( 21.7 % ; P < 0.0001 ) , non-HDL-C ( 13.5 % ; P < 0.0001 ) , ApoB ( 8.8 % ; P < 0.0001 ) , LDL-C ( 5.2 % ; P=0.0236 ) , and HDL-C levels ( 4.0 % ; P=0.0053 ) . CONCLUSIONS Compared with placebo , IPE 4 grams/day significantly lowered hsCRP levels and improved lipids without raising LDL-C levels in patients with metabolic syndrome and high ( ≥200 and < 500 mg/dL ) or very high ( ≥500 and ≤2000 mg/dL ) TG levels , with or without stable statin therapy .
71137
Intervention_Pharmacological
Icosapent Ethyl ( Eicosapentaenoic Acid Ethyl Ester )
71138
Intervention_Pharmacological
icosapent ethyl ( eicosapentaenoic acid ethyl ester , IPE )
71139
Intervention_Pharmacological
IPE
71140
Intervention_Control
placebo
71141
Outcome_Physical
significantly lowered hsCRP
71142
Outcome_Physical
significantly reduced hsCRP
71143
Outcome_Physical
non-high-density lipoprotein cholesterol ( non-HDL-C
71144
Outcome_Physical
apolipoprotein
71145
Outcome_Physical
raising LDL-C
71146
Participant_Condition
Patients With Metabolic Syndrome
71147
Participant_Condition
patients with metabolic syndrome , with and without stable statin therapy
71148
Participant_Condition
metabolic syndrome treated with IPE 4 grams/day
71149
Participant_Condition
metabolic syndrome
71150
Participant_Sample-size
n=204
71151
Participant_Condition
metabolic syndrome